Orakl Oncology (Seed)

Funding Details
Awarder
Inbox
Date Award
December 03, 2024
Vertical
Healthtech
Funding URL
View Funding Page
Funding Amount:
$11,000,000

Company Info
Founding Year
2023
Traction
Orakl plans to launch two new commercial products, O-Predict and O-Validate, to enhance drug development.
Organizations Involved
Gustave Roussy
Founders
Fanny Jaulin, Diane-Laure Pagès, Gustave Ronteix
Company Description
Orakl Oncology is a precision oncology company that has developed an AI-powered techbio platform combining real-world patient data with biology to improve drug development processes.
Market
Precision Oncology
Location
France
Coinvestors
Singular, Bpifrance

Links